Hjärtsvikt kostar! Klok läkemedelsanvändning kan kapa antalet dyra sjukhusdagar

Lakartidningen

Volumn , Issue 24, 1998, Pages 2828-2830

  Andersson, Fredrik ^a   Rydén Bergsten, Tina ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; FIBRINOLYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; CONGESTIVE HEART FAILURE; COST CONTROL; COST OF ILLNESS; DRUG UTILIZATION; ECONOMICS; HUMAN; LENGTH OF STAY;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; COST OF ILLNESS; COST SAVINGS; DRUG UTILIZATION; FIBRINOLYTIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; LENGTH OF STAY;

EID: 11544312192     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Rydén L. Vård vid hjärtsvikt kan bli bättre. Läkartidningen 1997; 94: 2369-72.
2. McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. British Journal of Medical Economics 1993; 6: 99.
3. van Hout B, Wielink G, Bonsel GJ, Rutten FH. Effects of ACE inhibitors on heart failure in the Netherlands. A pharmacoeconomic model. PharmacoEconomics 1993; 3: 387-97.
4. Parmley WW. Cost-effective management of heart failure. Clin Cardiol 1996; 19: 240.
5. Erhardt L, Caidahl K, Eriksson H, Persson H, Sylvén C. Hjärtsvikt. Stockholm: Socialstyrelsen, 1994. SoS-rapport 1994:3.
6. Nilsson CA, Carling K, Erlö CK, Myrén KJ. Vårdkostnader 1994. DRG-jämförelser av sjukhus och kliniker. Stockholm: Spri, 1996.
7. Johannesson M, Jönsson B. Ekonomisk utvärdering av läkemedel. Stockholm: SNS Förlag, 1993.
8. Olsson G, Levin LÅ, Rehnqvist N. Economic consequences of postinfarction prophylaxis with β blockers: cost effectiveness of metoprolol. BMJ 1987; 294: 339-42.
9. Levin LÅ, Jönsson B. Cost effectiveness of thrombolysis - a randomized study of intravenous rt-PA in suspected myocardial infarction. Eur Heart J 1992; 13: 2-8.
10. Johannesson M, Agewall S, Hartford M, Hedner T, Fagerberg B. The cost-effectiveness of cardiovascular multiple risk factor intervention programme in treated hypertensive men. J Intern Med 1995; 237: 19-26.
11. Erhardt L, Ball S, Andersson F, Bergentoft P, Martinez C. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE Study. PharmacoEconomics, 1997; 12: 256-66.
12. Johannesson M. The cost effectiveness of hypertension treatment in Sweden. PharmacoEconomics 1995; 7: 242-50.
13. SBU. Måttligt förhöjt blodtryck. Stockholm: SBU, 1994.
14. Johannesson M, Dahlöf B, Lindholm LH, Ekbom T, Hansson L, Oden A et al. The cost-effectiveness of treating hypertension in the elderly - an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med 1993; 234: 317-23.
15. Johannesson M, Wikstrand J, Jönsson B, Berglund G, Tuomilehto J. Cost-effectiveness of antihypertensive treatment - metoprolol versus thiazide diuretics. PharmacoEconomics 1993; 3: 36-44.
16. Lindgren B, Persson U. The cost-effectiveness of a new anti-hypertensive drug, doxazosin. Current Therapeutic Research 1989; 45: 738-60.
17. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17: 1001-7.
18. Johannesson M, Borgquist L, Jönsson B, Lindholm LH. The cost effectiveness of lipid lowering in Swedish primary health care. J Intern Med 1996; 240: 23-9.